Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06271616 · ClinicalTrials.gov registry record · Phase 2
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
A Phase 2 study of Hematopoietic and Lymphatic System Neoplasm and Chronic Graft Versus Host Disease, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06271616 is a Phase 2 study of Hematopoietic and Lymphatic System Neoplasm and Chronic Graft Versus Host Disease that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 40 participants, below the 483-participant average among 62 other Hematopoietic and Lymphatic System Neoplasm trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06271616, a Phase 2 study of Hematopoietic and Lymphatic System Neoplasm and Chronic Graft Versus Host Disease, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial tests how well ibrutinib works in preventing chronic graft-versus-host disease (GVHD) in patients undergoing donor (allogeneic) hematopoietic cell transplantation (HCT). An allogeneic hematopoietic cell transplantation (allo-HCT) is a treatment in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical donor. When healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets. However, sometimes the transplanted cells from a donor can attack the body's normal cells (called GVHD). Giving ibrutinib after the transplant may stop that from happening. Ibrutinib is in a class of medications called kinase inhibitors. It works by blocking a protein in the blood called Bruton's tyrosine kinase (BTK). By blocking BTK, ibrutinib inhibits certain immune cells that play a role in cGVHD. Giving ibrutinib after an allo-HCT may prevent the development of chronic GVHD.
Conditions Studied
Interventions
- PROCEDURE Echocardiography Test
- DRUG Ibrutinib
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-12-13 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06271616
The ClinicalTrials.gov registry entry for NCT06271616 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 62 other Hematopoietic and Lymphatic System Neoplasm trials with a reported enrollment target (92% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematopoietic and Lymphatic System Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Echocardiography Test is the first listed.
NCT06271616 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06271616 about?
NCT06271616 is a clinical study titled "Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant". This phase II trial tests how well ibrutinib works in preventing chronic graft-versus-host disease (GVHD) in patients undergoing donor (allogeneic) hematopoietic cell transplantation (HCT). An allogeneic hematopoietic cell transplantation (allo-HCT) is a treatment in which a person receives blood-fo...
What is the current status of trial NCT06271616?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2024-12-13. Estimated completion is 2027-06-30.
What conditions does trial NCT06271616 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphatic System Neoplasm, Chronic Graft Versus Host Disease.
What interventions are being tested in trial NCT06271616?
The interventions under investigation include: Echocardiography Test (PROCEDURE), Ibrutinib (DRUG).
Who is sponsoring clinical trial NCT06271616?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06271616 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphatic System Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
RECRUITING · Phase 2
-
Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial
RECRUITING · Phase 2
-
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
RECRUITING · Phase 2
-
Two Step Haplo With Radiation Conditioning
RECRUITING · Phase 2
Explore more on PlainTrial
Hematopoietic and Lymphatic System Neoplasm
All registered trials for this condition
Chronic Graft Versus Host Disease
All registered trials for this condition
Florida
All trials with a study site in Florida
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.